Sonelokimab
Based on 1 Customer Validation
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.81%
- CAS No.: 1414386-05-2
- Masse moléculaire:40.11 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
VH-VH'-VH, trivalent
Human
|
IL-17A |
IL-17F |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A collagen-induced arthritis model in cynomolgus monkey[4]
-
Dosage:2.8 and 10 mg/kg
-
Administration:weekly intervals for 8 consecutive weeks
-
Result:Significantly improved X-ray score B and the arthritis score in a collagen-induced arthritis model in cynomolgus monkey.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH'-VH, trivalent
ELISA, FACS, Functional assay
-
Loaded IL-17F Protein, Human (HEK293, His, HY-P70540) on NTA biosensor, can bind Sonelokimab with an affinity constant of 2.859E-10 M as determined in BLI assay. -
Loaded IL-17A (HEK293, His, HY-P70527) on NTA biosensor, can bind Sonelokimab with an affinity constant of <1.000E-11 M as determined in BLI assay.
Chemical Information
-
CAS No. 1414386-05-2
-
Appearance Liquid
-
Masse moléculaire 40.11 kDa
-
Color Colorless to light yellow
-
SMILES
[Sonelokimab]
-
Synonyms
ALX 0761; M 1095
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751-4. [Content Brief]
[2]. Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327. [Content Brief]
[3]. Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sonelokimab Related Classifications
HY-P99397 Related Classifications
Powered by Bioz